EFFECT OF OBESITY ON VEDOLIZUMAB RESPONSE IN INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Levine, Louis
Gaidos, Jill K.
Proctor, Deborah D.
Viana, Artur V.
Al Bawardy, Badr
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su465
引用
收藏
页码：S703 / S704
页数：2
相关论文
共 50 条
  • [1] Effect of obesity on vedolizumab response in inflammatory bowel disease
    Levine, Louis
    Gaidos, Jill K. J.
    Proctor, Deborah D.
    Viana, Artur V.
    Al-Bawardy, Badr
    [J]. ANNALS OF GASTROENTEROLOGY, 2022, 35 (03): : 275 - 280
  • [2] Predicting Response to Vedolizumab in Inflammatory Bowel Disease
    Meserve, Joseph
    Dulai, Parambir
    [J]. FRONTIERS IN MEDICINE, 2020, 7
  • [3] Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease
    Reider, S.
    Watschinger, C.
    Koch, R.
    Tilg, H.
    Moschen, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I522 - I522
  • [4] EFFECT OF VEDOLIZUMAB DOSE ESCALATION ON RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Shivashankar, Raina
    Ladd, Antonio H. Mendoza
    Grace, Rory
    Aberra, Faten
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S77 - S77
  • [5] Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease
    Shmidt, Eugenia
    Kochhar, Gursimran
    Hartke, Justin
    Chilukuri, Prianka
    Meserve, Joseph
    Chaudrey, Khadija
    Koliani-Pace, Jenna L.
    Hirten, Robert
    Faleck, David
    Barocas, Morris
    Luo, Michelle
    Lasch, Karen
    Boland, Brigid S.
    Singh, Siddharth
    Vande Casteele, Niels
    Sagi, Sashidhar Varma
    Fischer, Monika
    Chang, Shannon
    Bohm, Matthew
    Lukin, Dana
    Sultan, Keith
    Swaminath, Arun
    Hudesman, David
    Gupta, Nitin
    Kane, Sunanda
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Siegel, Corey A.
    Sands, Bruce E.
    Colombel, Jean-Frederic
    Shen, Bo
    Dulai, Parambir S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2461 - 2467
  • [6] Vedolizumab (Entyvio) for Inflammatory Bowel Disease
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2014, 56 (1451): : 86 - 88
  • [7] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
    Haddley, K.
    [J]. DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
  • [8] The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease
    Kamal, Natasha
    Marciano, Beatriz
    Curtin, Bryan
    Strongin, Anna
    DeRavin, Suk See
    Bousvaros, Athos
    Koh, Christopher
    Malech, Harry L.
    Holland, Steven M.
    Zerbe, Christa
    Heller, Theo
    [J]. GASTROENTEROLOGY REPORT, 2020, 8 (05): : 404 - 406
  • [9] Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease
    Elisa K. Boden
    Donna M. Shows
    Michael V. Chiorean
    James D. Lord
    [J]. Digestive Diseases and Sciences, 2018, 63 : 2419 - 2429
  • [10] Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease"
    Pauwels, Renske W. M.
    de Vries, Annemarie C.
    van der Woude, C. Janneke
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 (05) : E59 - E59
12345